A practical reference on alpha-MSH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-09 and is reviewed periodically as new material appears.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
An academic discipline – one with academic departments, curricula and degrees; national and international societies; and specialized journals. A scientific field (a branch of science) – widely recognized category of specialized expertise within science, and typically embodies its own terminology and nomenclature. Such a field will usually be represented by one or more scientific journals, where peer-reviewed research is published. There are several chemistry-related scientific journals. A natural science – one that seeks to elucidate the rules that govern the natural world using empirical and scientific method. A physical science – one that studies non-living systems. A biological science – one that studies the role of chemicals and chemical processes in living organisms. See Outline of biochemistry.
==== Hawaii ==== In Hawaii, where cuisine is heavily influenced by Asian cultures, glass noodles are known locally as long rice, supposedly because the process of making the noodles involves extruding the starch through a potato ricer. They are used most often in chicken long rice, a dish of glass noodles in chicken broth that is often served at luaus.
The three substrates of this enzyme are glutathione amide disulfide, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are glutathione amide and oxidised NAD+. Glutathione amide reductase is a dimeric flavoprotein (FAD).
The largest and sole study employing bicalutamide, an industry-sponsored, phase II, multicenter, international, open-label, single-arm clinical trial known as the Bicalutamide and Anastrozole Treatment of Testotoxicosis (BATT) study, assessed the combination of 12.5 to 100 mg/day bicalutamide and 0.5 to 1 mg/day anastrozole over a period of 12 months in 14 young boys with FMPP. The mean age of the boys was 4 ± 2 years, with a range of 2 to 9 years of age. At baseline, the boys weighed 23 ± 6 kg (52 ± 12 lbs) on average, with a range 17 to 35 kg (37 to 77 lbs). Mean total levels of testosterone in the boys were 277 ± 208 ng/dL at baseline and increased to 523 ± 258 ng/dL at 6 months and 427 ± 243 ng/dL at 12 months. Mean total levels of estradiol in the boys were 3.8 pg/mL at baseline and were relatively unchanged at 6 and 12 months (2.5 pg/mL and 3.5 pg/mL, respectively). The dosage of bicalutamide was initiated at 12.5 mg/day and was then increased, with adjustment as necessary to maintain trough circulating (R)-bicalutamide concentrations within a target range of 5 to 15 μg/mL. This range is similar to (R)-bicalutamide levels achieved with approximately 30 to 100 mg/day bicalutamide in adult men with prostate cancer. The mean final dosage of bicalutamide in the boys at 12 months was 60 ± 29 mg/day, with 86% of the boys on either 50 or 100 mg/day bicalutamide. Levels of (R)-bicalutamide were proportional to dosage and did not appear to be related to the age or weight of the boys.
Sources: en.wikipedia.org
acquired bowel herniation (this becomes a risk for larger donor sites (>4 cm)). About 20 cases have been reported in the literature from 1945 until 1989 and only a few hundred cases have been reported worldwide meralgia paresthetica (injury to the lateral femoral cutaneous nerve also called Bernhardt-Roth's syndrome) pelvic instability fracture (extremely rare and usually with other factors) injury to the clunial nerves (this will cause posterior pelvic pain which is worsened by sitting) injury to the ilioinguinal nerve infection minor hematoma (a common occurrence) deep hematoma requiring surgical intervention seroma ureteral injury pseudoaneurysm of iliac artery (rare) tumor transplantation cosmetic defects (chiefly caused by not preserving the superior pelvic brim) chronic pain Bone grafts harvested from the posterior iliac crest in general have less morbidity, but depending on the type of surgery, may require a flip while the patient is under general anesthesia.
=== Thirlwall inquiry === After Letby's conviction, the British government announced an independent inquiry into "the circumstances surrounding the deaths and incidents, including how concerns raised by clinicians were dealt with". It was initially established on a non‑statutory basis, meaning witnesses could not be compelled to give evidence and inquests would still be required. Senior figures at the Countess of Chester Hospital, including the medical director, chief executive and nursing director at the time of the incidents, said they would cooperate. The medical director retired in August 2018, and the chief executive resigned the following month after signing a non‑disclosure agreement. Families represented by the law firm Slater and Gordon called for the inquiry to be given statutory powers, arguing that a non‑statutory process relied on the goodwill of witnesses. Similar calls were made by former Justice Secretary Sir Robert Buckland, Chester MP Samantha Dixon, Steve Brine, chair of the Health and Social Care Select Committee, Sir Keir Starmer, then Leader of the Opposition, and the Parliamentary and Health Service Ombudsman. In August 2024, a group of 24 neonatal and statistical experts wrote to ministers requesting that the inquiry be postponed and its terms amended, citing concerns about the safety of Letby's convictions. The inquiry declined to make changes. Education Secretary Gillian Keegan said the type of inquiry would be reviewed once a chair was appointed.
The history of penicillin traces how observations of antibiotic activity in the mould Penicillium led to the development of penicillins, a family of widely used antibiotics. Ancient societies used moulds to treat infections, and many people observed the inhibition of bacterial growth by moulds. While working at St Mary's Hospital in London in 1928, Scottish physician Alexander Fleming was the first to show experimentally that a Penicillium mould secretes an antibacterial substance, which he named "penicillin". The mould was found to be a variant of Penicillium chrysogenum (now called Penicillium rubens), a contaminant of a bacterial culture in his laboratory. The work on penicillin at St Mary's ended in 1929. In 1939, a team of scientists at the Sir William Dunn School of Pathology at the University of Oxford, led by Howard Florey, which included Edward Abraham, Ernst Chain, Mary Ethel Florey, Norman Heatley and Margaret Jennings, began researching penicillin. They developed a method for cultivating the mould and extracting, purifying and storing penicillin from it, together with an assay for measuring its purity. "Penicillin" now became the name of the active ingredient in the mould juice. They carried out experiments on animals to determine penicillin's safety and effectiveness before conducting clinical trials and field tests. They derived penicillin's chemical formula and determined how it works. The private sector and the United States Department of Agriculture located and produced new strains and developed mass production techniques.
In 1973, Cold Storage's Pasaraya Malaysia, a joint venture of Cold Storage's subsidiary Supermarkets Malaysia and "Malaysian interests" was responsible for the construction of Jaya Supermarket in Petaling Jaya, set to be completed in April 1974. In 1985, Cold Storage Malaysia opened its first Majik Market store in Bangsar Baru, Kuala Lumpur, It operated under a franchise from Mumford Inc of Atlanta, USA, which complements its existing Jaya Supermarket chain but differ in concept and management. Due to competition from 7-Eleven, whose Malaysian franchise was then operated by the Antah Holdings group, Cold Storage Malaysia phased out Majik Market as part of its streamlining process. Cold Storage Malaysia, along with Peremba, Gaya Timur and Jusco were responsible for the initial version of Jaya Jusco "superstores" in 1985, with three stores in Dayabumi, Taman Tun Dr Ismail and Subang Jaya. In 1987, Cold Storage Malaysia, which had been through a difficult financial phase in the previous three years, had a change in management with some senior executives leaving. In 1992, DFI Retail Group purchased the company, although no major changes were made to the Cold Storage brand. Cold Storage started the Fresh Food Distribution Centre in Singapore in 1999, a composite multi-temperature warehousing for fresh and frozen food distribution. In 2023, DFI Retail Group divested its Malaysian food retailing business (including Cold Storage brand in that country) to Macrovalue Sdn Bhd.
=== Disorders === Hyperparathyroidism, the presence of excessive amounts of parathyroid hormone in the blood, occurs in two very distinct sets of circumstances. Primary hyperparathyroidism is due to autonomous, abnormal hypersecretion of PTH from the parathyroid gland, while secondary hyperparathyroidism is an appropriately high PTH level seen as a physiological response to hypocalcemia. A low level of PTH in the blood is known as hypoparathyroidism and is most commonly due to damage to or removal of parathyroid glands during thyroid surgery. There are a number of rare but well-described genetic conditions affecting parathyroid hormone metabolism, including pseudohypoparathyroidism, familial hypocalciuric hypercalcemia, and autosomal dominant hypercalciuric hypocalcemia. Of note, PTH is unchanged in pseudopseudohypoparathyroidism. In osteoporotic women, administration of an exogenous parathyroid hormone analogue (teriparatide, by daily injection) superimposed on estrogen therapy produced increases in bone mass and reduced vertebral and nonvertebral fractures by 45–65%.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.